Von Willebrand factor exacerbates heart failure through formation of neutrophil extracellular traps

• Published in: European heart journal 2024-10, Vol.45 (37), p.3853-3867
• Main Authors: Mang, Ge, Chen, Jianfeng, Sun, Ping, Ma, Ruishuang, Du, Jingwen, Wang, Xiaoqi, Cui, Jingxuan, Yang, Mian, Tong, Zhonghua, Yan, Xiangyu, Wang, Dongni, Xie, Huiqi, Chen, Yujia, Yang, Qiannan, Kong, Yingjin, Jin, Jiaqi, Wu, Jian, Zhang, Maomao, Yu, Bo
• Format: Article
• Language: English
• Subjects: ADAMTS13 Protein - genetics; ADAMTS13 Protein - metabolism; Animals; Disease Models, Animal; Extracellular Traps - metabolism; Heart Failure - metabolism; Humans; Male; Mice; Mice, Knockout; Myocytes, Cardiac - metabolism; Neutrophils - metabolism; Protein-Arginine Deiminase Type 4 - metabolism; Valsartan - pharmacology; von Willebrand Factor - metabolism
• ISSN: 0195-668X; 1522-9645; 1522-9645
• DOI: 10.1093/eurheartj/ehae517

Heart failure (HF) is a leading cause of mortality worldwide and characterized by significant co-morbidities and dismal prognosis. Neutrophil extracellular traps (NETs) aggravate inflammation in various cardiovascular diseases; however, their function and mechanism of action in HF pathogenesis remain underexplored. This study aimed to investigate the involvement of a novel VWF-SLC44A2-NET axis in HF progression. NET levels were examined in patients with HF and mouse models of transverse aortic constriction (TAC) HF. PAD4 knockout mice and NET inhibitors (GSK-484, DNase I, NEi) were used to evaluate the role of NETs in HF. RNA sequencing was used to investigate the downstream mechanisms. Recombinant human ADAMTS13 (rhADAMTS13), ADAMTS13, and SLC44A2 knockouts were used to identify novel upstream factors of NETs. Elevated NET levels were observed in patients with HF and TAC mouse models of HF. PAD4 knockout and NET inhibitors improved the cardiac function. Mechanistically, NETs induced mitochondrial dysfunction in cardiomyocytes, inhibiting mitochondrial biogenesis via the NE-TLR4-mediated suppression of PGC-1α. Furthermore, VWF/ADAMTS13 regulated NET formation via SLC44A2. Additionally, sacubitril/valsartan amplifies the cardioprotective effects of the VWF-SLC44A2-NET axis blockade. This study established the role of a novel VWF-SLC44A2-NET axis in regulating mitochondrial homeostasis and function, leading to cardiac apoptosis and contributing to HF pathogenesis. Targeting this axis may offer a potential therapeutic approach for HF treatment.